Preclinical studies demonstrated that FMD delayed tumor progression by reducing IgA-producing B cells and restoring CD8+ T-cell activity, thereby shifting the tumor microenvironment toward immunostimulation (71). This evidence concerns the gene CD79A and neoplasm.